Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Nutritional and Metabolic Diseases; Cardiovascular Diseases | 0.700 | 1.000 | 2 | 2011 | 2013 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Cardiovascular Diseases | 0.010 | < 0.001 | 1 | 2018 | 2018 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Stomatognathic Diseases | 0.010 | < 0.001 | 1 | 2018 | 2018 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Endocrine System Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Eye Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Stomatognathic Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Eye Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Digestive System Diseases; Neoplasms; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.700 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Digestive System Diseases; Neoplasms; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Nutritional and Metabolic Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Eye Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Cardiovascular Diseases | 0.700 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.683 | 0.480 | 9 | 22003224 | 3 prime UTR variant | C/T | snv | 0.32 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Eye Diseases | 0.050 | 0.800 | 5 | 2011 | 2017 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Eye Diseases | 0.810 | 1.000 | 3 | 2012 | 2012 | ||||||||
|
0.695 | 0.520 | 9 | 22003368 | 3 prime UTR variant | G/A;T | snv |
|
Neoplasms | 0.710 | 1.000 | 3 | 2009 | 2018 |